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Abstract
Accumulating evidence supports a link between depression and being overweight in women. Given previously
reported sex differences in fat accumulation and depression prevalence, as well as the likely role of sex hormones in
both overweight and mood disorders, we hypothesised that the depression-overweight association may be mediated
by sex hormones. To this end, we investigated the association of being overweight with depression, and then
considered the role of sex hormones in relation to being overweight and depression in a large population-based
cohort. We included a total of 3124 women, 970 premenopausal and 2154 postmenopausal from the LIFE-Adult
cohort study in our analyses. We evaluated associations between being overweight (BMI >25 kg/m2), sex hormone
levels, and depressive symptomatology according to Centre for Epidemiologic Studies Depression (CES-D) scores, and
explored mediation of depression in a mediation model. Being overweight was signiﬁcantly associated with
depressive symptoms in premenopausal but not postmenopausal women. Both premenopausal and postmenopausal
overweight women had higher free testosterone levels compared with normal weight women. Premenopausal
women with depressive symptomatology had higher free testosterone levels compared to women without. We found
a signiﬁcant mediation effect of depressive symptomatology in overweight premenopausal women through free
testosterone level. These ﬁndings highlight the association between being overweight and depressed, and suggest
that high free testosterone levels may play a signiﬁcant role in depression of overweight premenopausal women.
Based on this, pharmacological approaches targeting androgen levels in overweight depressed females, in particular
when standard anti-depressive treatments fail, could be of speciﬁc clinical relevance.
Introduction
The worldwide increasing prevalence of obesity and
depression are among the leading and most challenging
health problems faced today, particularly for women1–3.
In 2016, 40% of the world’s adult female population was
overweight and 15% of women were obese4, which is the
result of an accelerating rate for population-wide obesity
over recent decades5,6. Depression prevalence has also
increased at an alarming rate. Women have a lifetime risk
of major depression nearly twice that of men, approxi-
mately 5% of women will develop major depression, and
depression is expected to be the second leading cause of
disability worldwide by the year 20207. Studies have found
that higher rates of both depression and obesity diminish
quality of life and increase risk of morbidity and pre-
mature mortality8–10.
Beyond their independent impact on morbidity and
mortality, depression and obesity are highly comorbid,
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and their co-occurrence is largely associated with adverse
health3. Several large epidemiologic studies and meta-
analyses11,12 support an association between obesity and
depression, which appears to be stronger in women than
in men13–16. Moreover, being both overweight and
depressed is more prevalent in women than in men,
indicating a potential common underlying mechanism.
Chronic low-grade inﬂammation17, oxidative stress18,
metabolic and endocrinologic disturbances19,20 have been
suggested as possible contributing factors.
Given the observed sex differences in both adipose fat
accumulation and depression prevalence, it is likely that
sex hormones substantially inﬂuence the interplay
between obesity and depression. Sex hormones interact
with main neurotransmitter systems implicated in the
regulation of cognition and affect, including acetylcholine,
serotonin, dopamine, and norepinephrine21,22. Both
androgens and oestrogens play a role in emotional pro-
cessing, memory, and perception, as well as the inter-
pretation of sensory information in the hypothalamus and
hippocampus23, supporting a signiﬁcant role in the etio-
pathogenesis of major depressive disorder. Evidence from
several lines of research link hormone ﬂuctuations to
increased risk of developing a major depressive episode.
Firstly, vulnerability for depression in women signiﬁcantly
increases in puberty and declines after menopause24.
Secondly, postpartum and perimenopause phases and the
immediate period after a surgically induced menopause
(all of which are characterised by substantial changes in
sex hormone levels—particularly oestradiol) are asso-
ciated with a signiﬁcant increase in the risk of depression
in women with or without a previous history of depressive
symptoms25,26. Finally, studies in clinical populations
found associations between sex hormones, such as oes-
tradiol and testosterone, and depression. Sustained low
oestradiol levels have been observed in women with major
depressive disorder27,28, as well as clinical recovery from
depression during the postpartum period, perimenopause,
and postmenopause following restoration of stable oes-
tradiol levels28. Antidepressant effects of oestrogen were
observed in several animal studies29,30 and have been
shown to be dose and receptor-dependent31. While
alterations in testosterone levels are largely accepted to
inﬂuence the pathogenesis of depression in men32–35,
recent ﬁndings suggest that testosterone may play a cri-
tical role in depression susceptibility in women as well,
although the ﬁndings are mixed36–38. While the con-
centration of testosterone in women is ten times lower
than in men39, it has been shown that women are more
sensitive to it40. In a study of women with polycystic
ovarian syndrome, a state of hyperandrogenism, a four-
fold risk increase for depression independent of body
mass index (BMI) was found41. Several animal studies
have also indicated an anti-depressant effect of testos-
terone42,43 and this effect appears to be dose dependent39
Propensity towards development of obesity differs
between the sexes and has been linked to endogenous
changes in sex hormones: Increased body fat mass in
women was shown to be associated with alterations of sex
hormone levels44. Human adipose tissue represents an
intracrine source of androgen synthesis in females, con-
tributing to changes in circulating sex hormone levels and
dysregulation of the hypothalamic-pituitary-gonadal
axis45. Unlike in men, serum androgens positively corre-
late with increased BMI in women46. Moreover, it has also
been shown that the hormonal abnormalities are partly or
wholly reversible with weight loss, indicating a causality of
this relationship 47.
What remains uncertain is whether and how these BMI-
associated sex hormone alterations may impact mood and
depressive symptoms. We hypothesise that all three
conditions —increased BMI, alterations in sex hormone
levels, and depression are strongly interconnected. More
speciﬁcally, these hormonal changes may actually mediate
depression in overweight women. Here, we aim to repli-
cate the association between increased body weight and
depressive symptoms in a well-powered (n > 3000 women)
cohort and subsequently determine whether the associa-
tion between being overweight and depressed correlates
with sex hormone levels. Finally, we will investigate
whether sex hormone levels mediate the association
between being overweight and depressed (Fig. 1).
Patients and methods
Patients
Data presented in this study were obtained from the
Leipzig Research Centre for Civilisation Diseases (LIFE)
Adult Study, a population-based cohort study of adults
from the eastern part of Germany (Leipzig) with over
10,000 randomly selected participants. The objective of
the LIFE Adult Study is to investigate prevalence, early
onset markers, genetic predispositions, and the role of
lifestyle factors in major diseases of civilisation, including
metabolic diseases and depression. Written informed
consent was obtained from all participants. The study was
approved by the responsible institutional ethics board of
the Medical Faculty of the University of Leipzig (PV 2016-
274-04). The data privacy and safety concept of the study
was endorsed by the responsible data protection ofﬁcer48.
Medical history, medications
Participants were asked about medical diagnoses pre-
viously conﬁrmed by a physician. Seventy common
medical diagnoses were included in the interview. Data on
menstrual cycle (number of days/months/years since the
last menstrual period), parity, history of bilateral
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oophorectomy and hysterectomy, as well as past or pre-
sent use of contraception pills or hormonal replacement
therapy were included. Data on all other medications
taken within the past seven days before the study day were
gathered. Medications were identiﬁed by barcodes48, fol-
lowing The Anatomical Therapeutic Chemical Classiﬁ-
cation System (ATC) classiﬁcation.
Anthropometric measurements
Anthropometric measurements were assessed by
trained study personnel according to standardised pro-
tocols. Body weight was measured with an electronic scale
(SECA 701, Seca Gmbh & Co KG) with a precision of
0.01 kg; body height was assessed using a stadiometer
(SECA 240) to the nearest 0.1 cm. BMI was calculated
as weight in kilograms divided by the square of the
body height in metres. Underweight was assessed as
BMI < 18.5 kg/m2, normal weight as BMI > 18.5 and
<25 kg/m2, overweight as BMI > 25 kg/m2 (pre-obesity
BMI > 25 and 29.9 kg/m2 and obesity >30 kg/m2)11.
Depression screening
Current (within the last week) depressive symptoms
were evaluated by a self-report questionnaire, using the
German version of the Centre for Epidemiological Studies
Depression Scale (CES-D)—“Die Allgemeine
Depressionsskala-Langform” (ADS-L). This screening tool
is a reliable and valid instrument for detecting depressive
symptoms with broad applicability in the general popu-
lation. The CES-D (ADS-L) consists of 20 items and
ranges from 0 to 60, higher scores indicating more
depressive symptoms49. A score ≥23 is suggested to
indicate clinically relevant depressive symptoms50.
Hormonal analyses
Blood samples were collected between 7:00 and 10:30 a.m.
in a fasting state. Analyses of sex hormones (sex
hormone-binding globulin, oestradiol, total testosterone)
as well as albumin (for calculation of free testosterone)
were performed on fresh biospecimens on the day of
sample collection. Biochemical analysis was performed by
fully the automated Cobas system (Roche, Mannheim).
Intra-assay and inter-assay coefﬁcients of variation were
given exemplarily by 100 subsequent analyses during the
time of recruitment study participants: The results of sex
hormone-binding globulin were <3.4% for the range
between 25.4 and 54.2 nmol/L, the results of total tes-
tosterone were <4.9% for the range between 3.73 and
19.07 nmol/L, and the results for oestradiol were <4.3%
for the range between 387–2052 pmol/L. Free and bioa-
vailable testosterone were calculated using Vermeulen’s
formula51, and free oestradiol using the spreadsheet
method52. We used the classiﬁcation of the menopausal
status according to the Breast Cancer Surveillance Con-
sortium53 as follows: premenopausal (0–6 months since
the last menstrual period (LMP) or <45 years), perime-
nopausal (6–12 months since LMP), postmenopausal
(>12 months since LMP or ≥55 years or bilateral
oophorectomy).
Exclusion criteria
The total sample included 5167 women with a mean age
of 56.6 years (range 18.8–82.1 years) and mean BMI of
27.0 kg/m2 (range 16.1–56.7 kg/m2). Most of the women
were born in Germany (95%) and had a middle (52.8%) or
high (27.4%) educational status. Seventy percent of them
were married or living with a partner. Due to the possible
impact on either sex hormones, BMI or depression score,
we excluded all women who were using external hor-
mones or CNS drugs (with the exception of analgetics and
local anaesthetics), women with hypothyreosis and
hyperthyreosis, severe chronic renal, hepatic, or neuro-
logical diseases, had cancer within the last year, and
women who had already been diagnosed and treated
(pharmacologically or non-pharmacologically) for
depression within the last year. We also excluded peri-
menopausal and postpartum (1 year after delivery)
women, as both periods are related to ﬂuctuations in sex
hormones, BMI changes, and increased onset and pre-
valence of depressive and anxiety disorders24. Detailed
Fig. 1 Hypothesis. We tested the association between a depressive
symptomatology and overweight, b association between overweight
and depressive symptomatology with sex hormone levels, and c
whether the association between depression and overweight might
be mediated through altered sex hormone levels associated with
increased BMI. Step 1 in c shows an association between overweight
(≥25 kg/m²) and depressive symptomatology (CES-D ≥ 23 points). Step
2 in c shows an association between overweight and sex hormone
level and Step 3 in c shows an association between depressive
symptomatology, overweight, and sex hormone level
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exclusion criteria including ATC categories of excluded
medications are provided in Fig. 2.
Statistical analyses
The analyses were carried out separately for the groups
of premenopausal and postmenopausal women. Cate-
gories for being overweight (BMI > 25 kg/m2) and
depressed (CES-D ≥23 points) were used as discontinuous
variables similarly to other studies11,54. Comparison
between groups was tested using t-tests for continuous
data and by chi-square tests for binary data. Values for the
cohort description are given as mean ± SD. To assess the
potential mediating effect of sex hormone levels on the
relationship between being overweight and depressed, we
tested the mediation hypothesis as described by Baron
and Kenny54. Brieﬂy, testing mediation require three
regression models in which the following conditions are
met: (1) The predictor variable is signiﬁcantly correlated
with the outcome variable when ignoring the mediator
variable, (2) the predictor variable is signiﬁcantly corre-
lated with the mediator variable and (3) the effect of the
predictor variable on the outcome variable after control-
ling for the mediator variable should be greatly reduced or
become non-signiﬁcant (Fig. 1). For the third step, full
mediation occurs if the effect of the predictor variable on
the outcome variable becomes non-signiﬁcant after con-
trolling for the mediator, and a partial mediation occurs if
the effect becomes signiﬁcantly reduced but remains
signiﬁcant. Partial mediation means that the mediating
variable accounts for some (but not all) of the relationship
between the independent and dependent variable. In
our model, the predictor variable was being overweight
(BMI > 25 kg/m2) and the outcome variable was being
depressed (CES-D ≥23 points), both of which were
deﬁned as binary (present= 0, not present= 1). The
mediator variable (free testosterone levels) was entered as
a continuous variable. Enter binary logistic regression was
used for all three models. The signiﬁcance threshold for
all statistical analyses was set at <0.05, and all analyses
were performed using SPSS version 25.0 (IBM, NY, USA).
Results
Subjects included
The study sample included 3124 women of whom 970
(31.0%) were premenopausal (45 ± 6.6 years) and 2154
(68.9%) were postmenopausal (64.2 ± 8.0 years). In the
LIFE study (n =  9805)
Females 52.7% (n = 5167)
• Medications:
•G02 (other gynecologicals, n = 207)
•G03 (sex hormones and genital 
modulators, n = 746)
•H02 (systemic corticosteroids, n = 60)
• L02 (endocrine therapy, n = 57)
•N03 (antiepileptics, n = 110) (1,2,3)
•N04 (antiparkinsonics, n = 60)
•N05 (psycholeptics, n = 252)
•N06 (psychoanaleptics, n = 473)
•N07 (other CNS drugs, n = 58) 
•Diseases:
• hyper/hypothyreosis (n = 11)
• severe renal/hepatal/neurologic
disease/cancer last year (n = 206) 
• depression treated (n = 342)
Excluding process
(excluded n = 2043) 
Classification process of
included females (n = 3124)
Statistical analyses
1. hormones ↔ BMI
2. depression ↔ hormones
3. mediation of depression by 
BMI altered sex hormones
• Underweight (≤ 18.5 kg/m²)
(n = 25)
• Perimenopausal (n = 136 ) (6-
12 months since LMP)
• Postpartal (n = 28 ) (<1 year
after delivery)  






• Premenopausal (n = 970) (0-6 
months since LMP or < 45 
years)
• Postmenopausal (n = 2154) (>
12 months since LMP or ≥ 55
years or bilat. ovarectomy)
• Normal weight (18.6 - 24.9
kg/m²)
• Overweight (˃ 25 kg/m²)
• Pre-obesity (25–29.9 kg/m²)
• Obesity (>30 kg/m²)
Fig. 2 Study design. Exclusion criteria and classiﬁcation of females. G02, G03, H02, L02, N03-N07—ATC groups of therapeutics. BMI, body mass index;
LMP, last menstrual period
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group of premenopausal women, 54.3% were of normal
weight (mean BMI 22.1 ± 1.6 kg/m2) and 45.6% were over-
weight (28.4% were pre-obese, mean BMI 27.1 ± 1.4 kg/m2
and 17.2% were obese, mean BMI 35.1 ± 5.0 kg/m2). In the
group of postmenopausal women, 32% were of normal
weight (mean BMI 22.8 ± 1.5 kg/m2) and 67.7% were over-
weight (38.2% were pre-obese, mean BMI 27.4 ± 1.4 kg/m2
and 29.5% were obese, mean BMI 34.1 ± 4.1 kg/m2). Seven
hundred twenty-two women (73.6%) in the premenopausal
group and 1908 (88.0%) in the postmenopausal group were
parous.
Association between being overweight and depression
In the premenopausal group, we found signiﬁcantly
higher CES-D scores in overweight women compared
with women of normal weight (11.2 ± 7.7 vs. 10.0 ± 7.4,
p= 0.01). Overweight premenopausal women also had a
signiﬁcantly higher prevalence of depressive symptoma-
tology compared to women of normal weight (10.5% vs.
6.6%, p= 0.042) with the OR= 1.65 (CI= 1.032–2.651,
p= 0.036). In the postmenopausal group, we observed no
signiﬁcant differences in overweight versus women of
normal weight in depressive symptomatology (6.5% vs.
6.1%, p= 0.841; OR= 1.05, CI= 0.709–1.571, p= 0.796).
Among other factors associated with increased BMI, we
did not ﬁnd a signiﬁcant association of depressive symp-
tomatology with either waist circumference (89.0 ±
12.7 cm in group without vs. 87.4 ± 12.9 cm in group with
depressive symptomatology, p= 0.296 in premenopausal
and 95.3 ± 12.6 vs. 94.1 ± 12.5 cm, p= 0.339 in post-
menopausal women) waist-hip ratio (0.8 ± 0.1 vs. 0.8 ± 0.1,
p= 0.217 in premenopausal and 0.9 ± 0.1 vs. 0.9 ± 0.1,
p= 0.172 in postmenopausal women) or hs-CRP (1.4 ±
1.4 vs. 1.9 ± 2.7 mg/L, p= 0.627 in premenopausal and
2.1 ± 1.8 vs. 1.6 ± 1.5 mg/L, p= 0.133).
We also observed no signiﬁcant effect of parity on BMI
(25.3 ± 5.2 kg/m2 for nonparous vs. 26.0 ± 5.5 kg/m2 for
parous, p= 0.069 in the premenopausal group, and 28.2 ±
4.9 kg/m2 for nonparous vs. 27.8 ± 5.2 kg/m2 for parous,
p= 0.371 in the postmenopausal group, respectively),
prevalence of being overweight (41.3% in nonparous vs.
47.2% in parous, OR= 1.27, CI= 0.95–1.69, p= 0.124 in
the premenopausal, and 71.7% vs. 66.7%, OR= 0.79, CI=
0.59–1.05, p= 0.120 in the postmenopausal group), or
prevalence of depressive symptomatology (9.0% in non-
parous vs. 8.2% in parous, OR= 0.91, CI= 0.54–1.52, p=
0.689 in the premenopausal, and 3.9% vs. 6.7%, OR= 1.74,
CI= 0.87–3.49, p= 0.146 in the postmenopausal group,
respectively).
Associations of being overweight and depression with sex
hormone levels
Associations of being overweight with sex hormone
levels Compared with individuals of normal weight,
overweight (including both subgroups of pre-obese and
obese) women had lower levels of sex hormone binding
globulin (54.8 ± 27.5 vs. 84.2 ± 41.8 nmol/L, p < 0.001 in
premenopause, and 54.1 ± 23.5 vs. 73.1 ± 25.5 nmol/L, p <
0.001 in postmenopause), higher total testosterone level
(12.8 ± 8.3 vs. 8.9 ± 6.1 pmol/l, p < 0.001 in premenopause,
10.6 ± 7.5 vs. 7.5 ± 5.6 pmol/L, p < 0.001 in postmeno-
pause) and free testosterone level (for details see Fig. 3).
Because of ﬂuctuations of oestradiol levels during the
menstruation cycle in premenopausal women, the asso-
ciation of BMI with oestradiol levels in premenopausal
was assessed by Pearson’s partial correlations controlled
for age and phase of menstrual cycle. No signiﬁcant
association of BMI with serum oestradiol levels (R=
−0.022, p= 0.536) or free oestradiol levels (R= 0.055,
p= 0.120) in premenopausal women was found.
In postmenopausal overweight women, we found
signiﬁcantly lower oestradiol levels (73.2 ± 211.1 L−1, vs.
51.4 ± 149.4 pmol/L, p= 0.014) compared to women of
normal weight. We also found signiﬁcantly lower levels of
luteinizing hormone (30.8 ± 11.1 vs. 34.1 ± 13.7 U/L,
p < 0.001) and follicle-stimulating hormone (66.5 ± 24.8
vs. 76.4 ± 30.1 U/L, p < 0.001) in overweight women
compared to women of normal weight.
Association of depression with sex hormone levels
Premenopausal women who reported depressive symp-
toms had signiﬁcantly higher free testosterone levels
compared to women who did not report being depressed
(12.9 ± 9.1 vs. 10.4 ± 7.0 nmol/L, p= 0.032).
Postmenopausal women with positive depressive symp-
tomatology had signiﬁcantly lower levels of sex hormone-
binding globulin (56.0 ± 26.7 vs. 61.7 ± 28.0 nmol/L, p=
0.044) as well as luteinizing hormone (29.1 ± 12.4 vs.
32.1 ± 12.3 U/L, p= 0.016) (Fig. 4).
Sex hormone levels and the association of being overweight
and depression
Subsequently; we explored a potential mediation of
depression by sex hormone levels in overweight women
and found a signiﬁcant mediation effect in the pre-
menopausal group only. In postmenopausal women, we
did not ﬁnd any signiﬁcant association of being over-
weight and depression. In premenopausal women, we
then used the mediation model to examine the respective
associations (Fig. 1c): In the ﬁrst step of the model, we
report a signiﬁcant association (OR= 1.65, CI=
1.032–2.651, p= 0.036) of being overweight and depres-
sive symptomatology. We also observed a signiﬁcant
association of being overweight and free testosterone
levels in the second step (OR= 3.89, CI= 2.881–4.905,
p < 0.001). In the third step, we found that free testos-
terone (OR= 1.03, CI= 1.005–1.070, p= 0.022), but not
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Fig. 3 Levels of selected sex hormones in various BMI groups in premenopausal and postmenopausal females. a Sex hormone-binding
globulin, b total testosterone, c free testosterone, d oestradiol, e free oestradiol, f follicle-stimulating hormone, g luteinizing hormone. Values are
displayed as mean+ conﬁdential intervals of the mean. PeM, premenopausal females; PoM, postmenopausal females; NW, normal weight; POB, pre-
obese (>25 <30 kg/m2), OB, obese (>30 kg/m2), OW, overweight (>25 kg/m2). Signiﬁcant differences *p ≤ 0.05, **p < 0.01, and ***p < 0.001
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Fig. 4 Levels of selected sex hormones in premenopausal and postmenopausal women with and without presence of depressive
symptomatology. a Sex hormone-binding globulin, b total testosterone, c free testosterone, d oestradiol, e free oestradiol, f follicle-stimulating
hormone, g luteinizing hormone. Values are displayed as mean+ conﬁdential intervals of the mean. PeM, premenopausal females; PoM,
postmenopausal females; D, depressed/presence of depressive symptomatology (CES-D ≥ 23 points), ND, non-depressed/without presence of
depressive symptomatology. Signiﬁcant differences *p ≤ 0.05, **p < 0.01, ***p < 0.001
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being overweight (OR= 1.43, CI= 0.847–2.443, p=
0.178), was signiﬁcantly associated with depression (Fig. 5).
Discussion
Here, we present empirical data from a large
population-based cohort study for a link between being
overweight, being depressed, and sex hormone levels
before menopause. Given the rising rates of obesity and
depression worldwide, recent ﬁndings highlight that the
often-reported relationship between obesity and depres-
sion may be of a sex-speciﬁc nature55,56, and of particular
relevance in women. This important observation still
lacks evidence from large population-based cohort studies
for validation and for framing essential questions on
possible mechanisms underlying this relationship.
In this study, we ﬁrst replicated a positive association
between being overweight and being depressed in our
sample of 970 premenopausal women, previously repor-
ted in a smaller sample size55. We additionally provide
novel evidence for a link between sex hormone levels,
depression, and obesity in women during the reproductive
years. We found an association between premenopausal
free testosterone levels and being overweight, as well as
with depression. Further exploratory mediation analysis
suggests that depressive symptomatology in overweight
premenopausal women may be mediated via free testos-
terone levels.
Association of depression and being overweight
Several large epidemiological studies and a meta-
analysis report a positive association between being
overweight and depression11,57, and this association
appears to be more prevalent in women than in men11.
Increased total and regional percentage fat body mass
have been shown to be signiﬁcantly associated with
depression in both men and women in a recent study
conducted by Li and colleagues58. In one of the largest
studies to date (over 177,000 individuals)12, a signiﬁcantly
higher prevalence of depressive symptomatology was
found in overweight (both pre-obese and obese) women.
However, not all studies report consistent evidence for
an association between depression and being over-
weight59. These conﬂicting reports could be explained by
differences in sample characteristics and methods (e.g., a
variety in age range, sample sizes, methods of assessments
for depression, or anthropometric measurements). While
some studies claim that the association of depression and
obesity might be bilateral11, Geoffroy et al.57 argue that
obesity predicts subsequent depressive symptoms, but not
vice-versa, as supported by data from approximately
nineteen thousand individuals. In that study, they found
that obesity predicted depressive symptoms only in
females, who had been recruited at birth and were re-
assessed longitudinally for 50 years. Similarly, we replicate
the association of depression with increased body weight
in premenopausal women (45 ± 6.6 years) but not in
postmenopausal women (64.2 ± 8.0 years). This ﬁnding is
in line with a phenomenon that is often referred to as the
“Jolly Fat” hypothesis (a lower prevalence of depression
associated with a moderately increased in BMI in older
individuals) and has been supported by previous studies,
both for overweight men and overweight women in later
life60.
While we did observe a strong relationship between
depressive symptomatology and BMI in the pre-
menopausal group, there was no association between
CES-D scores and either waist hip ratio or waist cir-
cumference. This may indicate that it is not adipose
tissue distribution in premenopausal women inducing
depression but rather the general increase in overall
body weight exceeding a normal range. This speculation
could be partially supported by the fact that peripheral
type of obesity is typically predominant in pre-
menopausal women, rather than the more abdominal/
visceral fat accumulation pattern observed later in life
for women. Thus, measures such as waist hip ratio and
waist circumference may not yet be able to capture the
obesity-associated changes in mood in this younger
cohort.
Unlike other studies61,62, we also did not prove a sig-
niﬁcant association of depressive symptomatology with
hs-CRP, another factor associated with obesity. However,
our results might be inﬂuenced by the fact that hs-CRP
values were only available in a minor part of women, and
predominantly healthy participants.
Association of sex hormone levels and being overweight
We found higher total and free testosterone levels and
lower sex hormone-binding globulin levels in overweight
premenopausal and postmenopausal women compared
Fig. 5 Mediation model in premenopausal women. In Step 1, we
found a signiﬁcant positive association between being overweight
and depressive symptomatology. In Step 2, we found a signiﬁcant
association between being overweight and free testosterone level. In
Step 3, we found a signiﬁcant association between free testosterone
level, but not overweight, with depressive symptomatology. This
means a complete mediation of association between being
overweight and depressive symptomatology by free
testosterone level
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with women of normal weight. These ﬁndings are in
concordance with several other reports of an association
of increased BMI with a more androgenic proﬁle
(diminished sex hormone-binding globulin and elevated
free testosterone levels) in women, independent of
menopausal status63: Obese women, particularly those
with abdominal fat accumulation, tend to develop a
condition of functional hyperandrogenism. This is
because female adipose tissue is an intracrine source of
androgen synthesis, as preadipocytes convert androste-
nedione to testosterone and thus actively contribute to
androgen synthesis. This is most likely catalysed by 17-
HSD5. Circulating levels of dehydroepiandrosterone sul-
phate (DHEAS), a crucial androgen precursor, correlate
positively with truncal fat in women, whereas there is an
inverse correlation in men64. In line with these reports, we
found increased testosterone levels with increased BMI in
postmenopausal women. However, the average levels of
testosterone were still within reference ranges (Fig. S1).
We do not report a signiﬁcant correlation between
serum oestradiol levels and increased BMI in pre-
menopausal women. This ﬁnding is in concordance with
other studies which have shown that, although oestradiol
production in adipose tissue positively correlates with
BMI39, it does not seem to signiﬁcantly inﬂuence oestra-
diol levels in serum65.
We found signiﬁcantly lower oestradiol levels in post-
menopausal overweight women compared with post-
menopausal women of normal weight. This ﬁnding
corresponds with signiﬁcantly lower levels of luteinizing
hormone and follicle-stimulating hormone in overweight
postmenopausal group found also by other studies66,67.
Association of sex hormones and depression
Phases of steep hormonal ﬂuctuations, mostly during
perimenopause and the postpartum period26, or condi-
tions of sex hormone imbalance (such as hyperan-
drogenism in e.g., polycystic ovarian syndrome) are
undoubtedly associated with an increased risk of depres-
sion in women41,68. In our study, we excluded women
meeting these criteria to investigate whether sex hor-
mones levels are associated with depression outside these
high-risk situations. In line with previous studies, we
found signiﬁcantly higher levels of free testosterone in
premenopausal women with depressive symptomatology
compared with premenopausal women who do not report
any depressive symptomatology.
Several studies have reported an association of supra-
physiological testosterone levels in women and depres-
sion69. Interestingly, higher testosterone levels have also
been reported in women suffering from postpartum “baby
blues”70. Furthermore, elevated testosterone levels, toge-
ther with hypercortisolemia69, have been observed in
women with severe depression, suggesting an
overstimulation of the adrenal glands by hyperactivity of
the hypothalamic-pituitary-adrenal axis, which is closely
intertwined with gonadal steroid hormone synthesis and
activity71. However, not all studies report a consistent
association between depression and testosterone level in
women72. These inconsistencies could in part be driven
by the different designs of these studies, varying exclusion
criteria used, as well as the differences in classiﬁcation of
women according to the menopausal status and evaluat-
ing these associations for each group separately.
We did ﬁnd lower sex hormone-binding globulin levels
in postmenopausal women with depressive symptoma-
tology compared with healthy postmenopausal women.
We are aware of only of one study to date where such an
association of sex hormone-binding globulin levels and
depressive symptomatology was observed in early post-
menopausal women (<10 years after menopause)73. In a
rodent model, Caldwell and colleagues74 demonstrated
internalisation of sex hormone-binding globulin in the
hypothalamus, which might indicate a potential role of
sex hormone-binding globulin in the pathogenesis of
depression. Future epidemiologic studies are needed to
conﬁrm our ﬁndings of this association in
postmenopausal women.
The negative association that we observed in post-
menopausal women between depression and luteinizing
hormone has also been described in previous studies75,76.
In the study of Altman75, mean plasma luteinizing hor-
mone concentration in postmenopausal women suffering
from unipolar depressive disorder was 33% lower than
that of normal postmenopausal women.
Role of sex hormones in the association between being
overweight and depressed
To the best of our knowledge, this is the ﬁrst study to
examine the role of sex hormones as a potential mediator
in the interplay between obesity and depression in a large
population-based cohort. Our ﬁndings suggest that the
relationship between increased body weight and depres-
sion could be mediated by free testosterone levels. Several
lines of argument point towards the conclusion that the
correlation of testosterone levels with being overweight
and being depressed may not be purely coincidental: (1)
Hormonal transition periods, particularly functional
hyperandrogenic states, have been associated with
increased rates of depression. Testosterone levels have
been shown to signiﬁcantly increase serotonin transporter
binding77, thus suggesting that testosterone triggers a
depressed mood by inducing synaptic serotonergic
depletion via increased neuronal re-uptake. (2) Studies in
patients with major depressive disorder provide evidence
of a normalisation of increased testosterone levels by
standard antidepressant treatment78. (3) Severity of obe-
sity seems to be reﬂected by the extent of sex hormone
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alterations79 as well as by severity of depression11.
Moreover, the sex hormonal changes associated with
increased body weight accumulation seem to be reversible
with subsequent weight loss, which suggests body weight
to causally inﬂuence sex hormone levels.
These lines of evidence, as well as our data, support an
essential role of testosterone in mediating depression in
overweight premenopausal women. However, other fac-
tors should be considered. In addition to more char-
acteristic risk factors for depression in women (such as
age, ﬂuctuating sex hormone levels, and failures in
interpersonal relationships)80,81, speciﬁc psychosocial
pressures associated with increased body weight (such as
weight discrimination, low self-conﬁdence, and body-
dissatisfaction) may trigger or contribute to a depressed
phenotype, speciﬁcally in overweight women during their
reproductive years82. Within such a framework, a sex
hormone imbalance, associated and potentially exacer-
bated by abdominal fat tissue accumulation, could provide
a “vulnerable terrain” for developing depression80.
Hormonal changes according to the BMI were similar in
premenopausal and postmenopausal women (Fig. 3),
however, we did not ﬁnd signiﬁcant associations of
depression symptomatology with free testosterone levels
or being overweight in the postmenopausal group. This
indicates that additional factors in postmenopausal group
could play a role, e.g., hormonal sensitivity, absolute
hormonal levels that differed compared to premenopausal
group, and “Jolly Fat” hypothesis—lower prevalence of
depression in older overweight women60.
Strengths and limitations
To the best of our knowledge, our dataset, which
explored associations between BMI, sex hormones, and
depression in more than 3000 women, is the largest to
date. The adherence to the strict exclusion criteria
employed in the aim to show “clear associations” repre-
sents a second major strength of this study. Further,
anthropometric measurements were acquired by trained
and experienced study personnel, rather than based on
self-reports, which has been shown to limit data inter-
pretation in previous work83. We acknowledge that
additional information on menstrual phase would have
been valuable for the interpretation of oestradiol levels in
premenopausal women. However, as the blood-draw
could not be performed at the same menstrual cycle
phase in all subjects in this large cohort, we addressed this
concern by standardised use of adjusted levels of oestra-
diol for one (follicular) phase in all statistical analyses.
While this standardised approach does not reﬂect indi-
vidual phase, distributions of menstruation phases were
similar in all BMI groups, which suggests that our ﬁndings
are not substantially driven by menstrual cycle phase only.
We further acknowledge that we can only report
correlation and cannot infer causation because of the
cross-sectional nature of our data. While the mediation
analysis provides a snapshot of the potential relationship
and directions between variables, this approach is not
without limitations. Longitudinal studies, as well as
interventional designs are needed to ultimately clarify
causality and direction in the relationship of sex hor-
mones, obesity, and depression. By integrating sex hor-
mone data with depression scores and thorough
anthropometric measures in a large population-based
sample of more than 3000 women, we aim to provide the
critical evidence-based model for the role of sex hor-
mones in the relationship of obesity and depression,
which needs validation in further studies.
In conclusion, we have demonstrated how sex hormone
levels can be integrated into a risk model for depression in
overweight postmenopausal women by providing evi-
dence to suggest that higher free testosterone level may be
a mediating factor of depression in overweight pre-
menopausal women. As hyperandrogenism associated
with increased abdominal fat accumulation has been
shown to be reversible with weight loss84–86, our ﬁndings
emphasise the importance of maintaining a healthy body
weight for women in early adult and midlife for effective
treatment, and possibly prevention of depression in later
life. Based on this insight, pharmacological approaches
targeting androgen levels in overweight depressed
females, in particular when standard anti-depressive
treatments fail, could be of speciﬁc clinical relevance.
Acknowledgements
We thank all study participants. We very much appreciate the help of the
physicians who performed the clinical examinations and data collection. This
work was supported by LIFE—Leipzig Research Centre for Civilisation Diseases,
University of Leipzig. LIFE is funded by means of the European Union, by
means of the European Social Fund (ESF), by the European Regional
Development Fund (ERDF), and by means of the Free State of Saxony within
the framework of the excellence initiative. The Integrated Research and
Treatment Centre Adiposity Diseases is funded by the German Federal Ministry
of Education and Research (Grant 01EO1501). Dr Julia Sacher is supported by
funds of the Max Planck Society, the Society in Science—The Branco Weiss
Fellowship and the Brain and Behaviour Research Foundation (NARSAD Young
Investigator Grant). Juraj Stanik was supported by European Society for
Paediatric Endocrinology (ESPE) Research Fellowship.
Author details
1Institute of Social Medicine, Occupational Health and Public Health, University
of Leipzig, Leipzig, Germany. 2DIABGENE Laboratory, Institute of Experimental
Endocrinology, Biomedical Research Center, Slovak Academy of Sciences,
Bratislava, Slovakia. 3Department of Pediatrics, Medical Faculty at the Comenius
University, Bratislava, Slovakia. 4Department of Neurology, Max Planck Institute
for Human Cognitive and Brain Sciences, Leipzig, Germany. 5Emotion &
NeuroimaGinG (EGG) Lab, Max Planck Institute for Human Cognitive and Brain
Sciences, Leipzig, Germany. 6Department of Economic and Social Sciences &
Institute of Social Medicine, Rehabilitation Sciences and Healthcare Research
(ISRV), University of Applied Sciences Nordhausen, Nordhausen, Germany.
7LIFE-Leipzig Research Center for Civilization Diseases, University of Leipzig,
Leipzig, Germany. 8Institute for Medical Informatics, Statistics and
Epidemiology, University of Leipzig, Leipzig, Germany. 9Institute of Laboratory
Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig,
Leipzig, Germany. 10Center for Pediatric Research Leipzig, University Hospital
Stanikova et al. Translational Psychiatry           (2019) 9:160 Page 10 of 12
for Children & Adolescents, University of Leipzig, Leipzig, Germany. 11Clinic of
Cognitive Neurology, University of Leipzig, Leipzig, Germany
Conﬂict of interest
The authors declare that they have no conﬂict of interest.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Supplementary Information accompanies this paper at (https://doi.org/
10.1038/s41398-019-0487-5).
Received: 26 September 2018 Revised: 23 March 2019 Accepted: 2 April
2019
References
1. Kessler, R. C. & Bromet, E. J. The epidemiology of depression across cultures.
Annu. Rev. Public Health 34, 119–138 (2013).
2. Ng, M. et al. Global, regional, and national prevalence of overweight and
obesity in children and adults during 1980–2013: a systematic analysis for the
Global Burden of Disease Study 2013. Lancet 384, 766–781 (2014).
3. Jantaratnotai, N., Mosikanon, K., Lee, Y. & McIntyre, R. S. The interface of
depression and obesity. Obes. Res. Clin. Pract. 11, 1–10 (2017).
4. World Health Organization. Obesity and overweight. https://www.who.int/
news-room/fact-sheets/detail/obesity-and-overweight. (2017).
5. Baskin, M. L., Ard, J., Franklin, F. & Allison, D. B. Prevalence of obesity in the
United States. Obes. Rev. 6, 5–7 (2005).
6. Stevens, G. A. et al. National, regional, and global trends in adult overweight
and obesity prevalences. Popul. Health Metr. 10, 22 (2012).
7. Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T. & Murray C. J. Global and
regional burden of disease and risk factors, 2001: systematic analysis of
population health data. Lancet 367, 1747–1757 (2006).
8. Kozela, M. et al. The association of depressive symptoms with cardiovascular
and all-cause mortality in Central and Eastern Europe: prospective results of
the HAPIEE study. Eur. J. Prev. Cardiol. 23, 1839–1847 (2016).
9. Christensen, G. T., Maartensson, S. & Osler, M. The association between
depression and mortality—a comparison of survey—and register-based
measures of depression. J. Affect. Disord. 210, 111–114 (2017).
10. Aparicio, H. J. et al. Overweight, obesity, and survival after stroke in the Fra-
mingham Heart Study. J. Am. Heart Assoc. 6, e004721 (2017).
11. Luppino, F. S. et al. Overweight, obesity, and depression: a systematic review
and meta-analysis of longitudinal studies. Arch. Gen. Psychiatry 67, 220–229
(2010).
12. Zhao, G. et al. Depression and anxiety among US adults: associations with
body mass index. Int J. Obes. 33, 257–266 (2009).
13. Friedman, M. A. & Brownell, K. D. Psychological correlates of obesity: moving to
the next research generation. Psychol. Bull. 117, 3 (1995).
14. Markowitz, S., Friedman, M. A. & Arent, S. M. Understanding the relation
between obesity and depression: causal mechanisms and implications for
treatment. Clin. Psychol. 15, 1–20 (2008).
15. Atlantis, E. & Baker, M. Obesity effects on depression: systematic review of
epidemiological studies. Int. J. Obes. 32, 881 (2008).
16. Ma, J. & Xiao, L. Obesity and depression in US women: results from the
2005–2006 National Health and Nutritional Examination Survey. Obesity 18,
347–353 (2010).
17. Berk, M. et al. So depression is an inﬂammatory disease, but where does the
inﬂammation come from? BMC Med. 11, 200 (2013).
18. Bornstein, S. R., Schuppenies, A., Wong, M. L. & Licinio, J. Approaching the
shared biology of obesity and depression: the stress axis as the locus of gene-
environment interactions. Mol. Psychiatry 11, 892–902 (2006).
19. Hryhorczuk, C., Sharma, S. & Fulton, S. E. Metabolic disturbances connecting
obesity and depression. Front. Neurosci. 7, 177 (2013).
20. Monteagudo, P. T., Falcao, A. A., Verreschi, I. T. & Zanella, M. T. The imbalance of
sex-hormones related to depressive symptoms in obese men. Aging Male 19,
20–26 (2016).
21. Jovanovic, H. et al. Effects of estrogen and testosterone treatment on ser-
otonin transporter binding in the brain of surgically postmenopausal women
—a PET study. Neuroimage 106, 47–54 (2015).
22. McHenry, J., Carrier, N., Hull, E. & Kabbaj, M. Sex differences in anxiety and
depression: role of testosterone. Front. Neuroendocrinol. 35, 42–57 (2014).
23. Juraska, J. M., Sisk, C. L. & DonCarlos, L. L. Sexual differentiation of the ado-
lescent rodent brain: hormonal inﬂuences and developmental mechanisms.
Horm. Behav. 64, 203–210 (2013).
24. Lokuge, S., Frey, B. N., Foster, J. A., Soares, C. N. & Steiner, M. Depression in
women: windows of vulnerability and new insights into the link between
estrogen and serotonin. J. Clin. Psychiatry 72, e1563–e1569 (2011).
25. Newhouse, P. & Albert, K. Estrogen, stress, and depression: a neurocognitive
model. JAMA Psychiatry 72, 727–729 (2015).
26. Schmidt, P. J. et al. Effects of estradiol withdrawal on mood in women with
past perimenopausal depression: a randomized clinical trial. JAMA Psychiatry
72, 714–726 (2015).
27. Young, E. A., Midgley, A. R., Carlson, N. E. & Brown, M. B. Alteration in the
hypothalamic-pituitary-ovarian axis in depressed women. Arch. Gen. Psychiatry
57, 1157–1162 (2000).
28. Douma, S. L., Husband, C., O’Donnell, M. E., Barwin, B. N. & Woodend, A. K.
Estrogen-related mood disorders: reproductive life cycle factors. ANS Adv. Nurs.
Sci. 28, 364–375 (2005).
29. Azizi-Malekabadi, H., Pourganji, M., Zabihi, H., Saeedjalali, M. & Hosseini, M.
Tamoxifen antagonizes the effects of ovarian hormones to induce anxiety and
depression-like behavior in rats. Arq. Neuropsiquiatr. 73, 132–139 (2015).
30. Bastos, C. P. et al. Object recognition memory deﬁcit and depressive-like
behavior caused by chronic ovariectomy can be transitorialy recovered by the
acute activation of hippocampal estrogen receptors. Psychoneuroendocrinol-
ogy 57, 14–25 (2015).
31. Weiser, M. J., Wu, T. J. & Handa, R. J. Estrogen receptor-beta agonist diaryl-
propionitrile: biological activities of R- and S-enantiomers on behavior and
hormonal response to stress. Endocrinology 150, 1817–1825 (2009).
32. Schweiger, U. et al. Testosterone, gonadotropin, and cortisol secretion in male
patients with major depression. Psychosom. Med. 61, 292–296 (1999).
33. Seidman, S. N. & Walsh, B. T. Testosterone and depression in aging men. Am. J.
Geriatr. Psychiatry 7, 18–33 (1999).
34. Wang, C. et al. Transdermal testosterone gel improves sexual function, mood,
muscle strength, and body composition parameters in hypogonadal men. J.
Clin. Endocrinol. Metab. 85, 2839–2853 (2000).
35. Joshi, D. et al. Low free testosterone levels are associated with prevalence and
incidence of depressive symptoms in older men. Clin. Endocrinol. 72, 232–240
(2010).
36. Weber, B., Lewicka, S., Deuschle, M., Colla, M. & Heuser, I. Testosterone,
androstenedione and dihydrotestosterone concentrations are elevated in
female patients with major depression. Psychoneuroendocrinology 25, 765–771
(2000).
37. Giltay, E. J. et al. Salivary testosterone: associations with depression, anxiety
disorders, and antidepressant use in a large cohort study. J. Psychosom. Res. 72,
205–213 (2012).
38. Gettler, L. T. & Oka, R. C. Are testosterone levels and depression risk linked
based on partnering and parenting? Evidence from a large population-
representative study of US men and women. Soc. Sci. Med. 163, 157–167
(2016).
39. Celec, P., Ostatnikova, D. & Hodosy, J. On the effects of testosterone on brain
behavioral functions. Front Neurosci. 9, 12 (2015).
40. Durdiakova, J., Ostatnikova, D. & Celec, P. Testosterone and its
metabolites–modulators of brain functions. Acta Neurobiol. Exp. 71, 434–454
(2011).
41. Hollinrake, E., Abreu, A., Maifeld, M., Van Voorhis, B. J. & Dokras, A. Increased risk
of depressive disorders in women with polycystic ovary syndrome. Fertil. Steril.
87, 1369–1376 (2007).
42. Frye, C. A. & Walf, A. A. Depression-like behavior of aged male and female mice
is ameliorated with administration of testosterone or its metabolites. Physiol.
Behav. 97, 266–269 (2009).
43. Goel, N. & Bale, T. L. Organizational and activational effects of testosterone on
masculinization of female physiological and behavioral stress responses.
Endocrinology 149, 6399–6405 (2008).
44. Sidhu, S., Parikh, T. & Burman, K. D. in Endocrine Changes in Obesity (eds
Feingold, K. R., Anawalt, B., Boyce, A., Chrousos, G., Dungan, K., Grossman, A.,
et al.) (Endotext, South Dartmouth, MA, 2000).
Stanikova et al. Translational Psychiatry           (2019) 9:160 Page 11 of 12
45. Pasquali, R. & Vicennati, V. The abdominal obesity phenotype and insulin
resistance are associated with abnormalities of the hypothalamic-pituitary-
adrenal axis in humans. Horm. Metab. Res. 32, 521–525 (2000).
46. Taponen, S. et al. Hormonal proﬁle of women with self-reported symptoms of
oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. J.
Clin. Endocrinol. Metab. 88, 141–147 (2003).
47. Zumoff, B. & Strain, G. W. A perspective on the hormonal abnormalities of
obesity: are they cause or effect? Obes. Res. 2, 56–67 (1994).
48. Loefﬂer, M. et al. The LIFE-Adult-Study: objectives and design of a population-
based cohort study with 10,000 deeply phenotyped adults in Germany. BMC
Public Health 15, 691 (2015).
49. Stein, J. et al. Screening for depression by telephone using the German
version of the Center for Epidemiological Studies Depression Scale (CES-D).
Psychiatr. Prax. 41, 135–141 (2014).
50. Hautzinger, M. Psychotherapy of depression. Bundesgesundheitsblatt Gesundh.
Gesundh. 51, 422–429 (2008).
51. Vermeulen, A., Verdonck, L. & Kaufman, J. M. A critical evaluation of simple
methods for the estimation of free testosterone in serum. J. Clin. Endocrinol.
Metab. 84, 3666–3672 (1999).
52. Mazer, N. A. A novel spreadsheet method for calculating the free serum
concentrations of testosterone, dihydrotestosterone, estradiol, estrone and
cortisol: with illustrative examples from male and female populations. Steroids
74, 512–519 (2009).
53. Phipps, A. I. et al. Deﬁning menopausal status in epidemiologic studies: a
comparison of multiple approaches and their effects on breast cancer rates.
Maturitas 67, 60–66 (2010).
54. Baron, R. M. & Kenny, D. A. The moderator-mediator variable distinction in
social psychological research: conceptual, strategic, and statistical considera-
tions. J. Pers. Soc. Psychol. 51, 1173–1182 (1986).
55. Li, L., Gower, B. A., Shelton, R. C. & Wu, X. Gender-speciﬁc relationship between
obesity and major depression. Front. Endocrinol. 8, 292 (2017).
56. De Wit, L. et al. Depression and obesity: a meta-analysis of community-based
studies. Psychiatry Res. 178, 230–235 (2010).
57. Geoffroy, M. C., Li, L. & Power, C. Depressive symptoms and body mass index:
co-morbidity and direction of association in a British birth cohort followed
over 50 years. Psychol. Med. 44, 2641–2652 (2014).
58. Li, Y., Meng, L. & Sato, Y. Depression-related differences in lean body mass
distribution from National Health and Nutrition Examination Survey
2005–2006. J. Affect. Disord. 157, 1–7 (2014).
59. Hach, I. et al. Obesity and the risk for mental disorders in a representative
German adult sample. Eur. J. Public Health 17, 297–305 (2007).
60. Jasienska, G., Ziomkiewicz, A., Gorkiewicz, M. & Pajak, A. Body mass, depressive
symptoms and menopausal status: an examination of the “Jolly Fat”
hypothesis. Women’s. Health Issues 15, 145–151 (2005).
61. Yibulaiyin, H., Sun, H. & Yang, Y. Depression is associated with CRP SNPs in
patients with family history. Transl. Neurosci. 8, 201–206 (2017).
62. Tabatabaeizadeh, S. A. et al. There is an association between serum high-
sensitivity C-reactive protein (hs-CRP) concentrations and depression score in
adolescent girls. Psychoneuroendocrinology 88, 102–104 (2018).
63. Tchernof, A. et al. Reduced testosterone and adrenal C19 steroid levels in
obese men. Metabolism 44, 513–519 (1995).
64. Quinkler, M. et al. Androgen generation in adipose tissue in women with
simple obesity–a site-speciﬁc role for 17beta-hydroxysteroid dehydrogenase
type 5. J. Endocrinol. 183, 331–342 (2004).
65. Wang, F. et al. 17beta-Estradiol and estradiol fatty acyl esters and estrogen-
converting enzyme expression in adipose tissue in obese men and women. J.
Clin. Endocrinol. Metab. 98, 4923–4931 (2013).
66. Bjornerem, A. et al. Endogenous sex hormones in relation to age, sex, lifestyle
factors, and chronic diseases in a general population: the Tromso Study. J. Clin.
Endocrinol. Metab. 89, 6039–6047 (2004).
67. Wang, N. et al. Follicle-stimulating hormone associates with prediabetes and
diabetes in postmenopausal women. Acta Diabetol. 53, 227–236
(2016).
68. Weiner, C. L., Primeau, M. & Ehrmann, D. A. Androgens and mood dysfunction
in women: comparison of women with polycystic ovarian syndrome to
healthy controls. Psychosom. Med. 66, 356–362 (2004).
69. Baischer, W., Koinig, G., Hartmann, B., Huber, J. & Langer, G. Hypothalamic-
pituitary-gonadal axis in depressed premenopausal women: elevated blood
testosterone concentrations compared to normal controls. Psychoneur-
oendocrinology 20, 553–559 (1995).
70. Hohlagschwandtner, M., Husslein, P., Klier, C. & Ulm, B. Correlation between
serum testosterone levels and peripartal mood states. Acta Obstet. Gynecol.
Scand. 80, 326–330 (2001).
71. Viau, V. Functional cross-talk between the hypothalamic-pituitary-gonadal and
-adrenal axes. J. Neuroendocrinol. 14, 506–513 (2002).
72. Kische, H. et al. Longitudinal change instead of baseline testosterone predicts
depressive symptoms. Psychoneuroendocrinology 89, 7–12 (2018).
73. Colangelo, L. A. et al. Association of sex hormones and sex hormone-binding
globulin with depressive symptoms in postmenopausal women: the Multi-
ethnic Study of Atherosclerosis. Menopause 19, 877–885 (2012).
74. Caldwell, J. D., Shapiro, R. A., Jirikowski, G. F. & Suleman, F. Internalization of sex
hormone-binding globulin into neurons and brain cells in vitro and in vivo.
Neuroendocrinology 86, 84–93 (2007).
75. Altman, N., Sachar, E. J., Gruen, P. H., Halpern, J. S. & Eto, S. Reduced plasma LH
concentration in postmenopausal depressed women. Psychosom. Med. 37,
274–276 (1975).
76. Amsterdam, J. D., Winokur, A., Lucki, I. & Snyder, P. Neuroendocrine regulation
in depressed postmenopausal women and healthy subjects. Acta Psychiatr.
Scand. 67, 43–49 (1983).
77. Kranz, G. S. et al. High-dose testosterone treatment increases serotonin
transporter binding in transgender people. Biol. Psychiatry 78, 525–533
(2015).
78. Pope, H. G. Jr., Cohane, G. H., Kanayama, G., Siegel, A. J. & Hudson, J. I.
Testosterone gel supplementation for men with refractory depression: a
randomized, placebo-controlled trial. Am. J. Psychiatry 160, 105–111 (2003).
79. Zumoff, B. Hormonal abnormalities in obesity. Acta Med. Scand. Suppl. 723,
153–160 (1988).
80. Kendler, K. S. & Gardner, C. O. Sex differences in the pathways to major
depression: a study of opposite-sex twin pairs. Am. J. Psychiatry 171, 426–435
(2014).
81. Albert, P. R. Why is depression more prevalent in women? J. Psychiatry Neu-
rosci. 40, 219 (2015).
82. Sikorski, C., Spahlholz, J., Hartlev, M. & Riedel-Heller, S. G. Weight-based dis-
crimination: an ubiquitary phenomenon? Int. J. Obes. 40, 333–337
(2016).
83. Wegienka, G. & Baird, D. D. A comparison of recalled date of last menstrual
period with prospectively recorded dates. J. Women’s Health 14, 248–252
(2005).
84. Leenen, R., Van Der Kooy, K., Seidell, J., Deurenberg, P. & Koppeschaar, H.
Visceral fat accumulation in relation to sex hormones in obese men and
women undergoing weight loss therapy. J. Clin. Endocrinol. Metab. 78,
1515–1520 (1994).
85. Crave, J.-C. et al. Effects of diet and metformin administration on sex hormone-
binding globulin, androgens, and insulin in hirsute and obese women. J. Clin.
Endocrinol. Metab. 80, 2057–2062 (1995).
86. Escobar-Morreale, H. F., Botella-Carretero, J. I., Alvarez-Blasco, F., Sancho, J. & San
Millán, J. L. The polycystic ovary syndrome associated with morbid obesity
may resolve after weight loss induced by bariatric surgery. J. Clin. Endocrinol.
Metab. 90, 6364–6369 (2005).
Stanikova et al. Translational Psychiatry           (2019) 9:160 Page 12 of 12
